

Magnesium Supplementation in Vitamin D Deficiency

Pramod Reddy, MD* and Linda R. Edwards, MD

Background: Vitamin D and magnesium (Mg) are some of the most studied topics in medicine with enormous implications for human health and disease. Majority of the adults are deficient in both vitamin D and magnesium but continue to go unrecognized by many health care professionals.

Areas of Uncertainty: Mg and vitamin D are used by all the organs in the body, and their deficiency states may lead to several chronic medical conditions. Studies described in the literature regarding these disease associations are contradictory, and reversal of any of these conditions may not occur for several years after adequate replacement. One should consider the supplementation therapy to be preventative rather than curative at this time.

Data Sources: PubMed search of several reported associations between vitamin D and Mg with diseases.

Results: Vitamin D and Mg replacement therapy in elderly patients is known to reduce the non-vertebral fractures, overall mortality, and the incidence of Alzheimer dementia.

Conclusions: Vitamin D screening assay is readily available, but the reported lower limit of the normal range is totally inadequate for disease prevention. Based on the epidemiologic studies, ~75% of all adults worldwide have serum 25(OH)D levels of <30 ng/mL. Because of the recent increase in global awareness, vitamin D supplementation has become a common practice, but Mg deficiency still remains unaddressed. Screening for chronic magnesium deficiency is difficult because a normal serum level may still be associated with moderate to severe deficiency. To date, there is no simple and accurate laboratory test to determine the total body magnesium status in humans. Mg is essential in the metabolism of vitamin D, and taking large doses of vitamin D can induce severe depletion of Mg. Adequate magnesium supplementation should be considered as an important aspect of vitamin D therapy.

Keywords: vitamin D, magnesium, secondary hyperparathyroidism, ionized magnesium, Intracellular Electrolytes and Magnesium test

INTRODUCTION

Magnesium (Mg) and vitamin D directly regulate bone and muscle metabolism throughout the life span of the musculoskeletal system and are also essential for the absorption of dietary calcium and phosphorus. Chronic

vitamin D deficiency (VDD) and Mg deficiency are often associated with hypocalcemia. Chronic hypocalcemia may lead to secondary hyperparathyroidism and the resulting elevation in parathyroid hormone (PTH) increases the bone resorption in efforts to restore the serum calcium levels. This process may lead to a generalized decrease in bone mineral density, resulting in osteopenia and osteoporosis (osteodystrophy). Patients may present with bone pain, tenderness, muscle weakness, and difficulty walking with an increased risk of falls and fractures.

In this review article, we briefly discuss the homeostasis and interactions between Mg and vitamin D along with diagnostic and treatment options.

Division of General Internal Medicine, UF Health Jacksonville, Jacksonville, FL.

The authors have no conflicts of interest to declare.

**Address for correspondence: 653-1 West 8th St, 3rd floor, Faculty Clinic, Jacksonville, FL 32209. E-mail: pramod.reddy@jax.ufl.edu*

Mg HOMEOSTASIS

Recommended daily allowance (RDA) for men is 5–6 mg/kg body weight (eg, 70 kg male needs 350–400 mg of Mg) and 4–5 mg/kg body weight for women. Dietary intake of Mg is inadequate in most adults because the majority of the Mg is lost during food processing. Although drinking water accounts for ~10% of daily magnesium intake, food (spinach, nuts, and seeds) remain the richest source of Mg.¹ Only approximately 30% of the total dietary magnesium is absorbed in the small intestine, but higher absorption is possible in deficiency states. Magnesium excretion is mainly regulated by the kidney, where 70% of the filtered Mg is reabsorbed in the thick ascending limb of the loop of Henle. Mg is critical for adenosine triphosphate (ATP) production, DNA/RNA synthesis, and glucose metabolism. Mg also serves as a cofactor for hundreds of metabolic reactions in the body, including the vitamin D metabolism. Mg is also essential for the regulation of blood pressure, cardiac excitability, nerve transmission, and neuromuscular conduction.^{2–4}

Normal levels of Mg

The adult human body contains approximately 24 g of magnesium mostly (99%) contained in the bone, muscles, and soft tissues. Only a small fraction of the total body magnesium is present in the serum, which do not accurately reflect the total body stores. A normal serum Mg level (1.5–2.5 meq/L) may still be associated with moderate to severe deficiency.^{5–7}

Causes of magnesium deficiency in general population

Most adult humans do not get their recommended RDA via diet. Patients who are on chronic proton pump inhibitor therapy may develop magnesium deficiency from decreased absorption.^{8,9} Patients on chronic loop and thiazide diuretics may have increased renal Mg losses. Heavy alcohol consumption impairs the absorption and enhances the excretion of Mg. Consuming large doses of vitamin D products may induce depletion of Mg.

VITAMIN D HOMEOSTASIS

Vitamins are by definition organic compounds that cannot be synthesized by an organism but required to maintain good health. Vitamin D has been misclassified as a fat-soluble vitamin since its discovery in 1928, but it should be considered as a hormone because dermal synthesis is the major natural source.

Vitamin D is known to be utilized by the earliest life forms throughout the evolution for nearly a billion years.¹⁰ Vitamin D supplements are available in 2 natural inactive forms. Vitamin D2 (ergocalciferol) is not synthesized naturally in the body and fortified milk, and supplements are the main source. Vitamin D3 (cholecalciferol) is produced endogenously in human skin by ultraviolet (UV) radiation after sunlight exposure. Certain dietary sources (dried mushrooms, salmon) and vitamin supplements are also the sources of vitamin D3. Caucasians can generate approximately 20,000 IU of vitamin D3 after full-body exposure for 10–15 minutes. Prolonged exposure to sunlight does not produce toxic amounts of vitamin D3 because the excess precursors convert into biologically inactive compounds. The amount of vitamin D3 production varies with the amount of skin pigmentation, body mass, the amount of skin exposed, and the extent of UV protection, including clothing and sunscreens.

Absorbed inactive vitamin D is bound to vitamin D binding proteins in the circulation and requires 2 hydroxylations in the liver and kidney to become the active form of vitamin D (Figure 1). 25(OH)D serves as vitamin D reserve (4 weeks of half-life) in the body, and the 1,25(OH)₂D is considered the active form of vitamin D (15 hours of half-life), which functions via the activation of the vitamin D receptors (VDRs) in the target tissues.^{11–13}

Extrahepatic and extrarenal hydroxylations can occur in a number of tissues (pancreas, prostate, colon, skin, and osteoblasts), where intact vitamin D can be metabolized directly to the active hormone; for example, prostate cells and dermal keratinocytes are capable of both 25 and 1-alpha hydroxylation of the intact vitamin D.^{14–16} This local tissue ability to metabolize vitamin D is considered vital for the maintenance of tissue health, and VDD is implicated in the development of various diseases and cancers (Table 1). Most of these associations are unproven at this point, and there is a need for larger, randomized, multicenter studies.¹⁷

Vitamin D and Mg interactions

Several steps in the vitamin D metabolism depend on magnesium as a cofactor, such as vitamin D binding to vitamin D binding protein, 25(OH)D synthesis, 1,25(OH)₂D synthesis, 25-hydroxylase synthesis, and VDR expression for cellular effects (Figure 1). Mg deficiency can also decrease PTH synthesis and secretion and also the number of available VDRs in target cells.^{18–21} Serum 1,25(OH)₂D concentrations frequently remain low in patients with Mg deficiency despite vitamin D intake^{22–24} Mg deficiency is also known to cause vitamin D-resistant hypocalcaemia, which can only be corrected after the proper replacement of Mg.




FIGURE 1. Vitamin D metabolism and Mg interaction.

Taking large doses of vitamin D without Mg replacement has been shown to induce atherosclerosis in swine coronary arteries.²⁵

Causes of VDD in general population

Caucasians can generate approximately 20,000 IU of vitamin D₃ after full-body exposure for 10–15 minutes. But, wearing a sunscreen (protection factor of 30) reduces vitamin D synthesis in the skin by more than 95%. Certain Caucasians have variable responsiveness to UV-B radiation, resulting in VDD despite abundant sun exposure. Cutaneous production of vitamin D also declines with age.²⁶ Individuals with darker skin pigmentation may require 5–10 times more exposure to generate vitamin D compared with Caucasians. Obese patients may have decreased cutaneous synthesis of vitamin D. In chronic kidney disease (CKD) patients, active vitamin

D production progressively declines with the course of the disease. Patients with malabsorption syndromes are often unable to absorb the fat-soluble vitamin D. Patients on anticonvulsants (eg, phenytoin) and antiretroviral medications enhance the catabolism of 25(OH)D and 1,25(OH)₂D. Patients with chronic granulomatous disorders (sarcoidosis, tuberculosis, and chronic fungal infections), lymphomas, and primary hyperparathyroidism have increased metabolism of 25(OH)D to 1,25(OH)₂D, which may lead to VDD.

ASSESSMENT OF VITAMIN D STATUS

Clinicians typically obtain vitamin D levels while evaluating patients with metabolic syndrome and fasting

Table 1. Proposed disease associations due to vitamin D and Mg deficiency.

System	Disease associations
Central nervous system	Migraines,* cognitive decline, Alzheimer disease,* Parkinson's disease, epilepsy, neuropathy, and cerebrovascular disease (stroke)*
Ophthalmology	Dry eye syndrome, macular degeneration, myopia, uveitis, and diabetic retinopathy
Psychiatry	Depression, schizophrenia
Cardiovascular system	Hypertension,* atherosclerosis,* congestive heart failure,* atrial fibrillation*
Respiratory system	Asthma* and Chronic obstructive pulmonary disease
Gastrointestinal system	Inflammatory bowel disease, irritable bowel syndrome, autoimmune hepatitis, nonalcoholic fatty liver disease, chronic hepatitis C virus infection
Nephrology and electrolytes	Proteinuria reduction in patients with diabetic nephropathy, progression of CKD, hypocalcemia* and hypophosphatemia*
Endocrinology and metabolism	Obesity, metabolic syndrome, chronic fatigue syndrome, dyslipidemia, types 1 and 2 diabetes mellitus,* increased insulin resistance. Graves disease, and Hashimoto thyroiditis, primary hyperparathyroidism
Rheumatology	Ankylosing spondylitis, rheumatoid arthritis, and systemic lupus erythematosus
Musculoskeletal system	Frequent falls, fractures, arthralgia, fibromyalgia, myalgia, myopathy, statin myopathy, and rhabdomyolysis
Infectious diseases	Increased susceptibility to viral, bacterial, and mycobacterial infections, exacerbation of human immunodeficiency virus complications (opportunistic infections, disease progression and death)
Hematology	Anemia, thrombocytopenia
Critically ill patients	Excess mortality, longer length of stay, higher sepsis incidence, longer mechanical ventilation
Malignancies	Breast cancer, prostate cancer, colorectal cancer, and retinoblastoma
Obstetrics and gynecology	Adverse pregnancy outcomes, preeclampsia, 3-fold increased risk for bacterial vaginosis, obesity, premenstrual syndrome,* and urinary and fecal incontinence
Pediatrics	Vitamin D supplementation may lower the risk of type 1 diabetes by 80% and may significantly improve the left ventricular ejection fraction and myocardial performance index in infants with heart failure
Allergy and immunology	Increased skin allergy,* low immunity leading to infections
Dermatology	Atopy, psoriasis

*Magnesium deficiency independently implicated.

hyperglycemia. It is also a common practice to assess the vitamin D status in pregnancy, elderly patients, and patients with chronic medical conditions (diabetes, hypertension, chronic renal failure, and dyslipidemia). Diagnosing and treating VDD is beneficial in patients with statin myopathy because the majority of patients (87%–95%) may tolerate a statin rechallenge.^{27,28}

The 25-hydroxy vitamin D level should always be the initial screening test in patients suspected to have VDD, which typically reflects the sum of 25(OH)-D₂ and 25(OH)₂-D₃, irrespective of the form of supplementation used by the patients. Results are reported either in nanograms/milliliter or nanomoles/liter, and the conversion factor from nanograms/milliliter to nanomoles/liter is about 2.5. For example, if patient's level is 30 ng/mL,

multiplying it by 2.5 will convert to 75 in nanomoles per liter.

Serum vitamin D levels are typically reported by the laboratories with a range of 10–30 ng/mL. The lower limit of normal range reflects the necessary level to prevent the skeletal manifestations (eg, rickets), but it is totally inadequate for disease prevention.^{29,30} Based on the epidemiologic studies, approximately 75% of all adults worldwide have serum 25(OH)D levels of <30 ng/mL. A level of 30–40 ng/mL seems to be ideal for the prevention of premature mortality, depression, diabetes, metabolic syndrome, dyslipidemia, and cardiovascular disease. Much higher levels (50–80 ng/mL) are necessary to prevent dementia and certain malignancies. Most advantageous serum level for 25(OH)D

for disease prevention is 60 ng/mL, which is the highest amount generated by the sun.^{31–33}

Vitamin D replacement in general population

Oral dosing of vitamin D depends upon the nature and severity of the deficiency. Increase in serum 25(OH)D levels may occur more efficiently with D3 therapy compared with D2. Serum 25(OH)D levels may fall rapidly (14 days) to the baseline in patients treated with D2.^{34–36} Using vitamin D at intermittent mega doses (eg, 3,00,000 IU every 3 months) should be avoided because of increased fall and fracture risk in elderly patients.^{37–39} Daily doses of vitamin D3 starting at 5000 IU is widely available over the counter (OTC), which should be recommended for the patients. Vitamin D levels should be rechecked in 3–4 months, and the dose should be adjusted to achieve the most beneficial serum levels (60–80 ng/mL) for disease prevention. Once properly replenished, it is important to maintain the serum 25(OH)D level without fluctuations. Noncompliance leading to sharp decline in tissue 1,25(OH)2D levels could increase the risk of certain cancers.⁴⁰

Vitamin D replacement in patients with CKD and end-stage renal disease

Majority of end-stage renal disease (ESRD) patients suffer from both 25(OH)D deficiency and 1,25(OH)2D deficiency. Traditional vitamin D2/D3 agents can be used as the first therapy to treat secondary hyperparathyroidism associated with low circulating levels of 25-hydroxy vitamin D in stage-3 CKD patients. But, their use in patients with stage-4 CKD and ESRD may not significantly lower the PTH levels. The administration of active vitamin D (calcitriol or synthetic vitamin D analogs) is known to significantly lower the PTH levels and increase the survival in patients with ESRD. Calcitriol has a narrow therapeutic window because of the increased intestinal absorption of calcium and phosphorus, resulting in calciphylaxis. To counteract this effect, several synthetic analogues of active vitamin D have been developed that effectively suppresses PTH with minimal VDR activity in the intestine. All the synthetic vitamin D compounds are either D2 based (paricalcitol and doxercalciferol) or D3 based (maxacalcitol, alfacalcidol). It is considered beneficial to also elevate the 25(OH)D levels in patients taking active forms of vitamin D to facilitate the paracrine production in various tissues.^{40–42}

ASSESSMENT OF THE Mg STATUS

Serum and red blood cell assays

Mg in the circulation exists in different compartments of the body (serum, erythrocytes, leukocytes, and

www.americantherapeutics.com

thrombocytes). In the serum, magnesium circulates in either a free ionized form or protein/anion bound form. Ionized Mg is the biologically active form of Mg in the body, which can be measured either in the serum or within the red blood cells (RBC).

Total serum Mg assay

Serum Mg assays evaluate the protein bound fraction of Mg and levels are reported as 0.7–1.0 mmol/L (range, 1.7–2.4 mg/dL). Patients with normal serum Mg levels can be still intracellularly deficient.^{5–7} In patients with hypoalbuminemia, serum Mg assays may overestimate hypomagnesemia. Although serum calcium level can be corrected for hypoalbuminemia, there is no such calculation available for Mg correction.

Ionized serum Mg assay

Ionized magnesium in the serum has been studied extensively in critically ill patients with hypoalbuminemia. Hypomagnesemia in general is known to be associated with higher intensive care unit mortality.⁴³

Total RBC Mg assay

RBC Mg levels are known to correlate with Mg levels in both the peripheral tissues and brain. Low RBC Mg levels (despite normal serum Mg levels) may negatively correlate with acute asthma exacerbation.^{44–46}

Ionized RBC magnesium assay

This assay may provide reliable information on the functional magnesium status but not widely available.⁴⁷

Intracellular Electrolytes and Magnesium test

Tissue scrapings from sublingual epithelial cells are tested for magnesium in this assay. Although the assay is noninvasive, it is not covered by health insurance and is expensive for out-of-pocket payments.

Magnesium tolerance test

Urinary magnesium levels are tested after an infused magnesium loading dose, and the patient is considered deficient when <80% of the magnesium is excreted into the urine. False positives are common in patients with malnutrition, diuretic use, diarrhea, CKD, and cirrhosis.

RECOMMENDATION

It is difficult to reliably diagnose chronic Mg deficiency with any of the currently available assays.⁴⁸ It is easier to treat the patients with supplements when Mg deficiency is suspected.

American Journal of Therapeutics (2017) 0(0)

CLINICALLY AVAILABLE Mg COMPOUNDS

Magnesium supplements are available as magnesium oxide, magnesium chloride, magnesium citrate, magnesium taurate, magnesium orotate, and amino acid chelates (Table 2).

Importance of elemental Mg

It may seem easy to meet the Mg daily allowance with a single tablet of magnesium oxide 400 mg, which is widely available OTC. But, RDA is based on absorbed

quantity of elemental magnesium; for example, magnesium oxide 400 mg has only 241 mg of elemental Mg, out of which only 4%–20% is absorbed. Because only approximately 50 mg elemental Mg is absorbed even with the best possible absorption, patients may need to take 8 tablets to meet the daily requirements.

Mg supplements differ in the content of elemental Mg and bioavailability, but there is not sufficient evidence to suggest one form of Mg over another at this time.^{49–56} It is also important not to consume large quantities of Mg to meet the daily requirements. Patients should be encouraged to take 2–4 pills of any Mg preparation they can afford and tolerate along with

Table 2. Properties of commonly available magnesium supplements.

Magnesium supplement	Dose/elemental Mg content	Bioavailability, %	Comments
Magnesium oxide	400–500 mg (241–300 mg)	4–22.8	Most widely available low-cost supplement; may induce diarrhea
Magnesium hydroxide	(Milk of Magnesia) 15 mL = 500 mg	20–50	May induce diarrhea
Magnesium citrate	500 mg (80 mg) taken during the day with meals	30	Citrate may increase stomach acidity; may induce diarrhea
Magnesium malate	500 mg (56 mg) taken during the day with meals	—	Malic acid may increase stomach acidity
Magnesium fumarate	140 mg (107 mg)	80–85	—
Magnesium chloride (slow release)	535 mg (64 mg) taken during the day with meals. Transdermal form available	20	Slow release absorbs better but needs large doses to meet daily requirements. Chloride may induce stomach acid secretion
Magnesium lactate	84 mg of elemental magnesium per capsule	42	Well absorbed but need large doses to meet daily requirements
Magnesium aspartate	400 mg (100 mg elemental)	41–45	Well absorbed but need large doses to meet daily requirements
Chelated magnesium (magnesium glycinate)	Elemental Mg 100 mg per tablet. Taken at bedtime	23.5	Good choice in patients with intestinal resection. Least likely to cause diarrhea
Magnesium orotate	500 mg (31 mg)	—	Well absorbed but need large doses to meet daily requirements. May offer cardiac and neuronal protection
Magnesium aminoate	327 mg (125 mg)	—	Frequently combined with calcium; May increase survival rates in Congestive heart failure
Magnesium threonate	~50 mg elemental Mg	—	—
Transdermal or “topical” magnesium (gel, oil spray, or lotion)	Oil: 8 sprays (~1 mL) = 100 mg; 1 teaspoon (5 mL) = 560 mg; gel: 1 teaspoon = 490 mg; lotion: 1 teaspoon = 185 mg	—	Expensive alternatives to oral therapy but may provide better absorption

RDA is 420 mg/d for men and 320 mg/d for women.

American Journal of Therapeutics (2017) 0(0)

www.americantherapeutics.com

a diet rich in Mg. Magnesium supplementation should be done cautiously in patients with moderate CKD with 50%–75% dose reductions. Mg supplementation should be avoided in patients with advanced CKD and ESRD.⁵⁷

ADVERSE EFFECTS OF VITAMIN D AND Mg REPLACEMENT THERAPY

Early adverse effects

Most patients tolerate the vitamin D and Mg supplemental therapy without adverse effects. But, a small number of patients may develop new symptoms within the first week of initiating the therapy. Palpitations, low-grade fever, heat intolerance, dizziness, dry eyes, conjunctival erythema, coated tongue, dry mouth, and significantly increased thirst are reported by some patients. Patients report increased tendency for dehydration and may drink large quantities of water but without primary polyuria. Severe muscle cramps and tendon stiffness may occur in previously asymptomatic patients. Pain at the sites of old, healed, musculoskeletal injuries and tingling sensation of nerves are sometimes reported. Musculoskeletal symptoms are more pronounced in patients with statin myopathy who started the supplemental therapy.

Most of these clinical manifestations are not adequately explained by the current medical knowledge. One possible explanation is that human body adapts to vitamin D and Mg deficiency by downregulating several metabolic reactions, which are rapidly resumed after the replacement therapy. There is minimal correlation between the serum levels and clinical symptoms. For example, a patient with severe VDD (<10 ng/L) may remain asymptomatic before and after the replacement therapy, whereas patients with only mild deficiency (20 ng/L) may develop these symptoms. Some patients report recurrence of symptoms when new Mg supplements are added to isolated vitamin D therapy.

It can be frightening to the affected patients when muscle pains and fatigue occurs along with palpitations.⁵⁸ They commonly undergo vigorous laboratory testing (eg, creatinine kinase, renal function panel), which usually reveal normal results. Screening tests for diabetes mellitus frequently reveal elevated fasting glucose levels and hemoglobin A1C levels up to 5.9, without postprandial hyperglycemia.

Physicians should have an open mind when patients report any new symptoms during the prescribed therapy. It is also a useful practice to enquire about the use of OTC vitamin D and Mg supplements when evaluating these patients. Symptoms gradually resolve in 3–6 months,

and physicians should assure the patients about the benign nature of the condition. Patients should be encouraged to do daily walking and stretching of the affected limbs and gradual weight lifting exercises to avoid the tendon injury. Replacement therapy can be continued at lower doses, which is advised over completely stopping the therapy. Recurrence of these symptoms is common if patient chooses to stop the therapy and resume it at a later time.

Late adverse effects

Vitamin D toxicity

Serum 25(OH)D level of >150 ng/mL is a good threshold for identifying patients at the risk for developing toxicity.^{59,60} Toxicity is typically associated with hypercalcemia, hyperphosphatemia, low PTH, and hypercalciuria. Patients may manifest with severe bone pains and nephrolithiasis due to bone demineralization. When the serum calcium concentration exceeds 14 mg/dL, patients may present with confusion, polyuria, polydipsia, anorexia, vomiting, and muscle weakness. Emergent medical intervention is necessary to rapidly correct hypercalcemia to prevent mortality. Treatment typically includes aggressive saline hydration, calcitonin, bisphosphonates, and corticosteroids. Because the excess vitamin D is stored in adipose tissues, effects of toxicity may last for few months, and weekly monitoring of serum calcium levels are recommended.

Mg toxicity

Hypermagnesemia from Mg supplements is extremely rare but possible in patients with advanced CKD. Neuromuscular symptoms (muscle weakness, decreased tendon reflexes) occur commonly when the serum Mg level is more than 4.8 mg/dL. Severe hypermagnesemia can cause hypotension, complete heart block, and cardiac arrest. Administration of intravenous calcium along with cardiorespiratory support is needed until magnesium levels are reduced by hemodialysis.

REFERENCES

1. Jiang L, He P, Chen J, et al. Magnesium levels in drinking water and coronary heart disease mortality risk: a meta-analysis. *Nutrients*. 2016;8. doi: 10.3390/nu8010005. pii: E5.
2. Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. *Nutrients*. 2015;7:8199–8226.
3. Glasdam SM, Glasdam S, Peters GH. The importance of magnesium in the human body: a systematic literature review. *Adv Clin Chem*. 2016;73:169–193.
4. Sarrafzadegan N, Khosravi-Boroujeni H, Lotfizadeh M, et al. Magnesium status and the metabolic syndrome:

- a systematic review and meta-analysis. *Nutrition*. 2016; 32:409–417.
5. Ryzen E, Nelson TA, Rude RK. Low blood mononuclear cell magnesium content and hypocalcemia in normomagnesemic patients. *West J Med*. 1987;147:549–553.
 6. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. *Physiol Rev*. 2015;95:1–46.
 7. Moe SM. Disorders involving calcium, phosphorus, and magnesium. *Prim Care*. 2008;35:215–237.
 8. Janett S, Camozzi P, Peeters GG, et al. Hypomagnesemia induced by long-term treatment with proton-pump inhibitors. *Gastroenterol Res Pract*. 2015;2015:951768.
 9. William JH, Danziger J. Magnesium deficiency and proton-pump inhibitor use: a clinical review. *J Clin Pharmacol*. 2016;56:660–668.
 10. Holick MF. Vitamin D: a millenium perspective. *J Cell Biochem*. 2003;88:296–307.
 11. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. *J Clin Endocrinol Metab*. 2013;98:4619–4628.
 12. Kissmeyer A, Mathiasen IS, Latini S, et al. Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). *Endocrine*. 1995;3:263–266.
 13. Haddad JG, Matsuoka LY, Hollis BW, et al. Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest*. 1993;91:2552–2555.
 14. Flanagan JN, Young MV, Persons KS, et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. *Anticancer Res*. 2006;26:2567–2572.
 15. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *J Clin Endocrinol Metab*. 2001;86:888–894.
 16. Schuessler M, Astecker N, Herzig G, et al. Skin is an autonomous organ in synthesis, two-step activation and degradation of vitamin D(3): CYP27 in epidermis completes the set of essential vitamin D(3)-hydroxylases. *Steroids*. 2001;66:399–408.
 17. Jorde R, Grimnes G. Vitamin D and health: the need for more randomized controlled trials. *J Steroid Biochem Mol Biol*. 2015;148:269–274.
 18. Rodríguez-Ortiz ME, Canalejo A, Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. *Nephrol Dial Transplant*. 2014;29:282–289.
 19. Risco F, Traba ML. Bone specific binding sites for 1,25 (OH)2D3 in magnesium deficiency. *J Physiol Biochem*. 2004;60:199–203.
 20. McCoy H, Kenney MA. Interactions between magnesium and vitamin D: possible implications in the immune system. *Magn Res*. 1996;9:185–203.
 21. Rude RK, Adams JS, Ryzen E, et al. Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency. *J Clin Endocrinol Metab*. 1985;61:933–940.
 22. Lemay J, Gascon-Barré M. Responsiveness of the intestinal 1,25-dihydroxyvitamin D3 receptor to magnesium depletion in the rat. *Endocrinology*. 1992;130:2767–2777.
 23. Zittermann A. Magnesium deficit? Overlooked cause of low vitamin D status? *BMC Med*. 2013;11:229.
 24. Deng X, Song Y, Manson JE, et al. Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. *BMC Med*. 2013;11:187.
 25. Ito M, Cho BH, Kummerow FA. Effects of a dietary magnesium deficiency and excess vitamin D3 on swine coronary arteries. *J Am Coll Nutr*. 1990;9:155–163.
 26. Cabral MA, Borges CN, Maia JM, et al. Prevalence of vitamin D deficiency during the summer and its relationship with sun exposure and skin phototype in elderly men living in the tropics. *Clin Interv Aging*. 2013;8:1347–1351.
 27. Khayznikov M, Hemachandra K, Pandit R, et al. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. *N Am J Med Sci*. 2015;7:86–93.
 28. Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. *Curr Med Res Opin*. 2011;27:1683–1690.
 29. Granado Lorenzo F, Blanco-Navarro I, Pérez-Sacrsitán B. Critical evaluation of assays for vitamin D status. *Curr Opin Clin Nutr Metab Care*. 2013;16:734–740.
 30. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. *Calcif Tissue Int*. 2013;92:118–127.
 31. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. *Adv Exp Med Biol*. 2014;810:500–525.
 32. Spedding S, Vanlint S, Morris H, et al. Does vitamin D sufficiency equate to a single serum 25-hydroxyvitamin D level or are different levels required for non-skeletal diseases? *Nutrients*. 2013;5:5127–5139.
 33. Autier P, Boniol M, Pizot C, et al. Vitamin D status and ill health: a systematic review. *Lancet Diabetes Endocrinol*. 2014;2:76–89.
 34. Heaney RP, Recker RR, Grote J, et al. Vitamin D(3) is more potent than vitamin D(2) in humans. *J Clin Endocrinol Metab*. 2011;96:E447–E452.
 35. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr*. 2012;95:1357–1364.
 36. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr*. 2003;77:204–210.
 37. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA*. 2010;303:1815–1822.
 38. Sanders KM, Nicholson GC, Ebeling PR. Is high dose vitamin D harmful? *Calcif Tissue Int*. 2013;92:191–206.
 39. Smith H, Anderson F, Raphael H, et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men

- and women—a population-based, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)*. 2007;46:1852–1857.
40. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. *Anticancer Res*. 2009;29:3675–3684.
 41. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. *Kidney Int*. 2011;79:702–707.
 42. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int*. 2007;72:1004–1013.
 43. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. *QJM*. 2016;109:453–459.
 44. Xiong W, Liang Y, Li X, et al. Erythrocyte intracellular Mg(2+) concentration as an index of recognition and memory. *Sci Rep*. 2016;6:26975.
 45. Basso LE, Ubbink JB, Delpont R. Erythrocyte magnesium concentration as an index of magnesium status: a perspective from a magnesium supplementation study. *Clin Chim Acta*. 2000;291:1–8.
 46. Amin M, Abdel-Fattah M, Zaghloul SS. Magnesium concentration in acute asthmatic children. *Iran J Pediatr*. 2012;22:463–467.
 47. Malon A, Brockmann C, Fijalkowska-Morawska J, et al. Ionized magnesium in erythrocytes—the best magnesium parameter to observe hypo- or hypermagnesemia. *Clin Chim Acta*. 2004;349:67–73.
 48. Millart H, Durlach V, Durlach J. Red blood cell magnesium concentrations: analytical problems and significance. *Magnes Res*. 1995;8:65–76.
 49. Zhang X, Del Gobbo LC. The circulating concentration and 24-h urine excretion of magnesium dose- and time-dependently respond to oral magnesium supplementation in a meta-analysis of randomized controlled trials. *J Nutr*. 2016;146:595–602.
 50. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. *Magnes Res*. 2001;14:257–262.
 51. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. *Am J Ther*. 2001;8:345–357.
 52. Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. *JPEN J Parenter Enteral Nutr*. 1994;18:430–435.
 53. Lindberg JS, Zobitz MM, Poindexter JR, et al. Magnesium bioavailability from magnesium citrate and magnesium oxide. *J Am Coll Nutr*. 1990;9:48–55.
 54. Classen HG. Magnesium orotate—experimental and clinical evidence. *Rom J Intern Med*. 2004;42:491–501.
 55. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). *Int J Cardiol*. 2009;134:145–147.
 56. Zeana C. Magnesium orotate in myocardial and neuronal protection. *Rom J Intern Med*. 1999;37:91–97.
 57. Mountokalakis TD. Magnesium metabolism in chronic renal failure. *Magnes Res*. 1990;3:121–127.
 58. Höck AD. Review: vitamin D3 deficiency results in dysfunctions of immunity with severe fatigue and depression in a variety of diseases. *In Vivo*. 2014;28:133–145.
 59. Vieth R. Vitamin D toxicity, policy, and science. *J Bone Miner Res*. 2007;22(suppl 2):V64–V68.
 60. Jones G. Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr*. 2008;88:582S–586S.